A program for individual and population optimal design for univariate and multivariate response pharmacokinetic-pharmacodynamic models

被引:40
|
作者
Gueorguieva, Luelina
Ogungbenro, Kayode
Graham, Gordon
Glatt, Sophie
Aarons, Leon
机构
[1] Lilly Res Ctr Ltd, Global PK PD, Windlesham GU20 6PH, Surrey, England
[2] Univ Manchester, Sch Pharm & Pharmaceut Sci, Ctr Appl & Pharmacokinet Res, Manchester M13 9PL, Lancs, England
[3] Pfizer Ltd, Sandwich CT13 9NJ, Kent, England
关键词
D-optimal design; multivariate response; pharmacokinetics; pharmacodynamics;
D O I
10.1016/j.cmpb.2007.01.004
中图分类号
TP39 [计算机的应用];
学科分类号
081203 ; 0835 ;
摘要
The design of pharmacokinetic and pharmacodynamic experiments concerns a number of issues, among which are the number of observations and the times when they are taken. often a model is used to describe these data and the pharmacokinetic-pharmacodynamic behavior of a drug. Knowledge of the data analysis model at the design stage is beneficial for collecting patient data for parameter estimation. A number of criteria for model-oriented experiments, which maximize the information content of the data, are available. In this paper we present a program, Popdes, to investigate the D-optimal design of individual and population multivariate response models, such as pharmacokinetic-pharm aco dynamic, physiologically based pharmacokinetic, and parent drug and metabolites models. A pre-clinical and clinical pharmacokinetic-pharmacodynamic model describing the concentration-time profile and effect of an oncology compound in development is used for illustration. (c) 2007 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:51 / 61
页数:11
相关论文
共 50 条
  • [41] Population Pharmacokinetic-Pharmacodynamic Model of Craving in an Enforced Smoking Cessation Population: Indirect Response and Probabilistic Modeling
    Roberto Gomeni
    Vincenzo Teneggi
    Laura Iavarone
    Lisa Squassante
    Alan Bye
    [J]. Pharmaceutical Research, 2001, 18 : 537 - 543
  • [42] Population pharmacokinetic-pharmacodynamic model of craving in an enforced smoking cessation population: Indirect response and probabilistic modeling
    Gomeni, R
    Teneggi, V
    Iavarone, L
    Squassante, L
    Bye, A
    [J]. PHARMACEUTICAL RESEARCH, 2001, 18 (04) : 537 - 543
  • [43] Dosage Optimization of Nemolizumab Using Population Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Modeling and Simulation
    Saito, Tomohisa
    Iida, Satofumi
    Terao, Kimio
    Kumagai, Yuji
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 57 (12): : 1564 - 1572
  • [44] Population Pharmacokinetic-Pharmacodynamic Analysis of Trastuzumab-Associated Cardiotoxicity
    van Hasselt, J. G. C.
    Boekhout, A. H.
    Beijnen, J. H.
    Schellens, J. H. M.
    Huitema, A. D. R.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 90 (01) : 126 - 132
  • [45] Reporting a Population Pharmacokinetic-Pharmacodynamic Study: A Journal's Perspective
    Jamsen, Kris M.
    McLeay, Sarah C.
    Barras, Michael A.
    Green, Bruce
    [J]. CLINICAL PHARMACOKINETICS, 2014, 53 (02) : 111 - 122
  • [46] Pharmacokinetic-pharmacodynamic models for topotecan-induced neutropenia.
    Chatelut, E
    Loos, WJ
    Léger, F
    Canal, P
    Bugat, R
    Verweij, J
    Sparreboom, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 140S - 140S
  • [47] Guiding Dyslipidemia Treatment: A Population Pharmacokinetic-Pharmacodynamic Framework for Obicetrapib
    Dunn, Allison
    Ditmarsch, Marc
    Kastelein, John J. P.
    Kling, Douglas
    Neild, Annie
    Davidson, Michael H.
    Gobburu, Joga
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 64 (09): : 1150 - 1164
  • [48] Population-based approach to the assessment of pharmacokinetic-pharmacodynamic data
    Troconiz, IF
    [J]. METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 1996, 18 : 51 - 52
  • [49] A population pharmacokinetic-pharmacodynamic and logistic regression analysis of lotrafiban in patients
    Mould, D
    Chapelsky, M
    Aluri, J
    Swagzdis, A
    Samuels, R
    Granett, E
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (04) : 210 - 222
  • [50] Pharmacokinetic-Pharmacodynamic Modeling of Apratastat: A Population-Based Approach
    Shu, Cathye
    Zhou, Honghui
    Afsharvand, Mehri
    Duan, Larry
    Zhang, Hui
    Noveck, Robert
    Raible, Donald
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (04): : 472 - 481